Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Differing Perceptions between Myelodysplastic Syndrome (MDS) Patients and Providers Regarding Blood Transfusions

David J. King, BS, Martina C. Murphy, MD, Rodney A. Schmidt, PhD, Matthew Lesser, MS, Alice Houk, MPS, Ellen Salkeld, PhD, Christopher R. Cogle, MD

Blood (2019) 134 (Supplement_1): 5418.

https://doi.org/10.1182/blood-2019-123474

Published: 2019

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

CRISPR Dropout Screens Identify DHODH, PIK3C3 , and Crkl as Potential Therapeutic Targets in Acute Myeloid Leukemia

Gregory Takacs, BS, Yujia Zhou, BS,BA, David J. King, BS, Amy Meacham, MS, Loguinov Alex, PhD, Abderrahmane Tagmount, PhD, Amin Sobh, PhD, Max Russo, BS, Chris D Vulpe, MD PhD, Christopher R. Cogle, MD

Blood (2019) 134 (Supplement_1): 1452.

https://doi.org/10.1182/blood-2019-128180

Published: 2019

Journal Articles

WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)

Brett M Stevens, PhD, Amanda Winters, MDPhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Yashaswini S Ullal, B.E, Ilu Kumari, M.Sc., Anuj Tyagi, M.Sc., Aftab Alam, M.Sc., Neelesh Lunkad, M.Tech, Leylah M. Drusbosky, PhD, Christopher R. Cogle, MD, Shireen Vali, PhD, Daniel A Pollyea, MD

Blood (2018) 132 (Supplement 1): 1538.

https://doi.org/10.1182/blood-2018-99-114429

Published: 2018

Journal Articles

Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort

Shireen Vali, PhD, Christopher R. Cogle, MD, Neeraj Arora, MD, Krishnan Shekhar, PhD, Mammen Chandy, MD, Manju Sengar, MD DM, Hasmukh Jain, MD DM, Girish Chinnaswamy, MD MRCP, Neeraj Kumar Singh, B.Tech, Shahabuddin Usmani, M.Sc., Anusha Pampana, M.Sc., Vijayashree P Shyamasundar, M.Sc., Huzaifa Sikora, B.Tech, Ansu Kumar, M.Sc., Taher Abbasi, MS, MBA, Vivek S Radhakrishnan, MDDM,MSc

Blood (2018) 132 (Supplement 1): 1539.

https://doi.org/10.1182/blood-2018-99-116603

Published: 2018

Journal Articles

Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study

Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Stephen E Kurtz, PhD, Cristina E. Tognon, PhD, Leylah M. Drusbosky, PhD, Robinson Vidva, B.Tech, Yugandhara Narvekar, M.Sc., Ashish Kumar Agrawal, B.V.Sc, A.H., Saji Gera, M.Tech, Samiksha Avinash Prasad, M.Sc., Vijayashree P Shyamasundar, M.Sc., Gaurav Singh Tunwer, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 1540.

https://doi.org/10.1182/blood-2018-99-115284

Published: 2018

Journal Articles

Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study

Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Leylah M. Drusbosky, PhD, Diwyanshu Sahu, M.Sc., Robinson Vidva, B.Tech, Shweta Kapoor, M.Sc., Humera Azam, M.Sc., Rajeev Kumar, B.Tech, Padmagiri G Chickdipatti, B.E, Nithya T Raveendaran, M.Tech, Reshma P Gopi, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2018-99-115678

Published: 2018

Journal Articles

AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow

Christopher R. Cogle, MD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Mohammed Sauban, B.E, Rahul K Raman, M.Sc., Robinson Vidva, B.Tech, Anuj Tyagi, M.Sc., Anay Ashok Talawdekar, M.Tech, Arko Das, M.Sc., Steven M. Kornblau, MD, Fieke W Hoff, BSc, Terzah M. Horton, MD PhD, Shireen Vali, PhD

Blood (2018) 132 (Supplement 1): 4034.

https://doi.org/10.1182/blood-2018-99-115775

Published: 2018

Journal Articles

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Chandan Kumar, M.Tech, Rakhi Purushothaman Suseela, B.Tech, Mamatha Patil, B.E, Patil Nilesh Dattatraya, M.Sc., Krishna Kumar Tiwari, B.Tech, Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 5506.

https://doi.org/10.1182/blood-2018-99-114466

Published: 2018

Journal Articles

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Andrej Besse, M.Sc, Christopher R. Cogle, MD, Leylah M. Drusbosky, PhD, Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Neha G Gupta, M.Sc., Abha Kushwaha, M.Sc., Pallavi Kumari, M.Sc., Karthik Sundara Raju, M.Sc., Ganesh Naga, B.Tech, Sayani Basu, M.Tech, Christoph Driessen, MD, Lenka Besse, PhD

Blood (2018) 132 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2018-99-116939

Published: 2018

Journal Articles

Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study

Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Shahabuddin Usmani, M.Sc., Deepak Anil Lala, B.Tech, Poornachandra G, B.Tech, Saumya Radhakrishnan, B.Tech, Shivgonda C Birajdar, MCA, Ganesh Naga, B.Tech, Leylah M. Drusbosky, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 3086.

https://doi.org/10.1182/blood-2018-99-115821

Published: 2018

Journal Articles

Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Yashaswini S Ullal, B.E, Sirisha Narayanabhatia, M.Sc., Aktar Alam, BCA, Kunal Ghosh Roy, M.Sc., Ashish Choudhary, M.Sc., Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2018-99-114610

Published: 2018

Journal Articles

Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Disease Registry

Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami S. Komrokji, MD, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, Chrystal U. Louis, E. Dawn Flick, Melissa Nifenecker, Pavel Kiselev, Arlene S. Swern, David P. Steensma

Blood (2018) 132 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2018-99-111145

Published: 2018

Journal Articles

Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect ® MDS/AML Disease Registry

Sudipto Mukherjee, MD PhD MPH, Mehrdad Abedi, MD, Harry P. Erba, MD PhD, Daniel A Pollyea, MD, Gail J. Roboz, MD, Michael A. Thompson, MD PhD FASCO, Chrystal U. Louis, E. Dawn Flick, Melissa Nifenecker, Pavel Kiselev, Arlene S. Swern, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 4736.

https://doi.org/10.1182/blood-2018-99-112935

Published: 2018

Journal Articles

Computational Modeling of Protein Networks Predicts Treatment Outcomes in Multiple Myeloma (MM)

Leylah M. Drusbosky, PhD, Hemant S. Murthy, MD, Helen L. Leather, Himanshu Grover, MS, Yugandhara Narvekar, MS, Pallavi Kumari, MS, Sirisha Narayanabhatia, MS, Priyanka Bhowmick, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Qing Zhang, PhD, Saad Z Usmani, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 592.

https://doi.org/10.1182/blood.V130.Suppl_1.592.592

Published: 2017

Journal Articles

Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Robinson Vidva, BT, Saji Gera, MT, Arko Das, MS, Krishna K Tiwari, BT, Vishwas Joseph, MS, Subrat Mohapatra, MS, Neelesh Lunkad, MT, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3907.

https://doi.org/10.1182/blood.V130.Suppl_1.3907.3907

Published: 2017

Journal Articles

Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Robinson Vidva, BT, Saji Gera, MT, Anjanasree V. Lakshminarayana, BE, Vijayashree P. Shyamasundar, MS, Ashish Kumar Agrawal, BS, Anay Talawdekar, MT, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3908.

https://doi.org/10.1182/blood.V130.Suppl_1.3908.3908

Published: 2017

Journal Articles

Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Madeleine Turcotte, MS, Paul Castillo, MD, Robinson Vidva, BT, Saji Gera, MT, Mohammed Sauban, BE, Priyanka Bhargav, BE, Punya Deep, MS, Shweta Kapoor, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3909.

https://doi.org/10.1182/blood.V130.Suppl_1.3909.3909

Published: 2017

Journal Articles

Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood (2017) 130 (Supplement 1): 3910.

https://doi.org/10.1182/blood.V130.Suppl_1.3910.3910

Published: 2017

Journal Articles

Poor Graft Function Following Autologous Stem Cell Transplant (ASCT): A Retrospective Analysis over Two Decades at a Transplant Center

Forat Lutfi, MD, William Paul Skelton, IV, MD, Emma Rosenau, Nosha Farhadfar, MD, Hemant S. Murthy, MD, W. Stratford May, MD PhD, John W. Hiemenz, MD, Christopher R. Cogle, MD, Randy A. Brown, MD, Sarah Wheeler, RPH, John R. Wingard, MD, Maxim Norkin, MD

Blood (2017) 130 (Supplement 1): 4529.

https://doi.org/10.1182/blood.V130.Suppl_1.4529.4529

Published: 2017

NARROW

Differing Perceptions between Myelodysplastic Syndrome (MDS) Patients and Providers Regarding Blood Transfusions

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

CRISPR Dropout Screens Identify DHODH, PIK3C3 , and Crkl as Potential Therapeutic Targets in Acute Myeloid Leukemia

WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)

Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort

Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study

Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study

AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study

Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System

Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Disease Registry

Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect ® MDS/AML Disease Registry

Computational Modeling of Protein Networks Predicts Treatment Outcomes in Multiple Myeloma (MM)

Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study

Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study

Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study

Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Poor Graft Function Following Autologous Stem Cell Transplant (ASCT): A Retrospective Analysis over Two Decades at a Transplant Center

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only